MT 100 coming to the UK

MT 100, an oral migraine drug from Pozen, was been approved in the UK on Monday (28 Nov).  The drug contains naproxen sodium and metoclopramide.  Naproxen sodium is familiar to migraineurs, it reduces pain and inflammation, and is often used for migraine brought on by hormonal changes.  Metoclopramide has been used to reduce pain and decrease nausea (it’s worked well for children with migraine).  It also enhances the effect of naproxen sodium by accelerating it’s absorption.

Pozen gave up on MT 100 in the USA when the FDA expressed concerns that it may cause tardive dyskinesia, a rare disorder of the nervous system.  Pozen argues that the drug is meant to be used intermittently, so the danger is minimal.

Pozen will be looking for distributors for the UK and various other countries.